Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

14.44 +0.05 (+0.35%)
Streaming Delayed Price Updated: 3:46 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 150,124
Open 14.35
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 14.39
Today's Range 14.40 - 14.44
52wk Range 12.82 - 16.91
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years
The multibillionaire's portfolio features some moneymaking ideas. 
Via The Motley Fool
Why Is Seagen Stock Trading Higher Today?
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:  
Via Benzinga

Performance

YTD
-5.12%
-5.12%
1 Month
-3.93%
-3.93%
3 Month
-5.00%
-5.00%
6 Month
+1.76%
+1.76%
1 Year
+10.14%
+10.14%

More News

Read More
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
Via Investor's Business Daily
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
Via Benzinga
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Via MarketBeat
Topics Economy
Exposures Interest Rates
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin
Via Investor's Business Daily
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Via Benzinga
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
Via Talk Markets
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
Why Shares of Annexon Are Plummeting Thursday
Via The Motley Fool
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
Via Benzinga
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
Via Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
Via The Motley Fool
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
Via Benzinga
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Via Investor's Business Daily
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Via Benzinga
Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move
Via Benzinga
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
Via Benzinga
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
Via Benzinga
Japanese Government Urges China To Release Astellas Pharma's Employee
Via Benzinga
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
Via Benzinga
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Via Benzinga
'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover
Via Investor's Business Daily
Super Bowl Commercials 2023: The Complete List Of Super Bowl LVII Ads And The Companies Behind Them
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.